Experimental cell therapy targets hard-to-treat ovarian cancers
NCT ID NCT06342986
Summary
This early-stage trial is testing whether a modified immune cell therapy called FT536 can help control recurrent ovarian, fallopian tube, or primary peritoneal cancers. Participants receive chemotherapy followed by FT536 delivered directly into the abdomen through a temporary catheter. The study aims to determine if this approach is safe and can delay cancer progression in people who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.